SQZ Biotechnologies EBITDA 2020-2022 | SQZ

SQZ Biotechnologies ebitda from 2020 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
SQZ Biotechnologies Annual EBITDA
(Millions of US $)
2021 $-58
2020 $-40
2019 $-31
SQZ Biotechnologies Quarterly EBITDA
(Millions of US $)
2022-03-31 $-18
2021-12-31 $-9
2021-09-30 $-20
2021-06-30 $-16
2021-03-31 $-13
2020-12-31 $-15
2020-09-30 $-10
2020-06-30 $-7
2020-03-31 $-8
2019-12-31
2019-09-30 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.094B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10